CONTRIBUTORS

Sleep Neurology p. 840-844 August 2020, Vol.26, No.4 doi: 10.1212/01.CON.0000695084.94876.c1
CONTRIBUTORS
BROWSE ARTICLES

Charlene Gamaldo, MD, FAAN, FAASM, Guest Editor

Professor, Vice-Chair, Faculty Development, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland

Relationship Disclosure: Dr Gamaldo has served on the board of directors for the American Academy of Neurology, has received personal compensation as a consultant for Jazz Pharmaceuticals, Inc, and has received publishing royalties from UpToDate, Inc.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Gamaldo reports no disclosure.

Sabra M. Abbott, MD, PhD

Assistant Professor of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois

Relationship Disclosure: Dr Abbott has received personal compensation for serving as a member of the American Board of Internal Medicine’s Sleep Medicine Exam Writing Committee, research/grant support from the American Sleep Medicine Foundation (155-JF-16), and publishing royalties from UpToDate, Inc.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Abbot discusses the unlabeled/investigational use of melatonin for the treatment of circadian rhythm sleep-wake disorders.

Sara E. Benjamin, MD

Clinical Associate, Instructor in Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland

Relationship Disclosure: Dr Benjamin has received personal compensation for a grand rounds presentation for Mercy Medical Center; as a narcolepsy agent formulary review consultant for OptumRx, Inc; and for occasional surveys for BioPharm, Compass, Inc, Everyday Health Group, GLG, InCrowd, Inc, J Reckner Associates, Inc, M3 Global Research, Olson Research Group, Research Now Group, LLC, Schlesinger Group, and WebMD, LLC.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Benjamin reports no disclosure.

Diego Garcia-Borreguero, MD, PhD

Medical Director, Sleep Research Institute, Madrid, Spain

Relationship Disclosure: Dr Garcia-Borreguero has received grant support from Merck & Co, Inc.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Garcia-Borreguero reports no disclosure.

Celia Garcia-Malo, MD

Specialist in Neurology, Sleep Research Institute, Madrid, Spain

Relationship Disclosure: Dr Garcia-Malo has received grant/research support from Accord Healthcare and the International RLS Study Group.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Garcia-Malo reports no disclosure.

Michael J. Howell, MD, FAAN

Vice-Chair, Education, Department of Neurology, University of Minnesota, Minneapolis, Minnesota

Relationship Disclosure: Dr Howell has received personal compensation for serving as an editor for MedLink Corporation, as a speaker for the American Academy of Dental Sleep Medicine, and as a speaker and consultant for the Sleep Performance Institute. Dr Howell has received grant support from the National Institute of Neurological Disorders and Stroke (1R01NS110613-01) and publishing royalties from UpToDate, Inc.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Howell discusses the unlabeled/investigational use of clonazepam for the treatment of rapid eye movement sleep behavior disorder.

Joseph S. Kass, MD, JD, FAAN

Associate Dean, Office of Student Affairs; Professor of Neurology, Psychiatry, and Medical Ethics; Director, Alzheimer’s Disease and Memory Disorders Center, Baylor College of Medicine; Chief of Neurology, Ben Taub General Hospital, Houston, Texas

Relationship Disclosure: Dr Kass serves as associate editor of medicolegal issues for Continuum, as an associate editor for Continuum Audio, as a neurology section editor of Ferri’s Clinical Advisor for Elsevier, and as co-editor of Neurology Secrets, Sixth Edition. Dr Kass has received personal compensation for CME lectures from Pri-Med LLC and as a principal investigator for clinical trials for Alzheimer disease from Biogen, Eisai Co, Ltd, Eli Lily and Company, National Institutes of Health, Novartis AG, and Roche Diagnostics.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Kass reports no disclosure.

Douglas B. Kirsch, MD, FAAN

Medical Director, Sleep Medicine, Atrium Health, Charlotte; Clinical Professor, UNC School of Medicine, Chapel Hill, North Carolina

Relationship Disclosure: Dr Kirsch has served as president of the American Academy of Sleep Medicine and receives publishing royalties from Elsevier and UpToDate, Inc.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Kirsch reports no disclosure.

Amy Licis, MD, MSCI

Associate Professor, Department of Neurology, Washington University School of Medicine in St. Louis, St. Louis, Missouri

Relationship Disclosure: Dr Licis has received personal compensation for serving as a moderator for Pediatric Update.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Licis discusses the unlabeled/investigational use of medications, none of which are approved by the US Food and Drug Administration for pediatric use except for sodium oxybate and amphetamines for the treatment of narcolepsy.

Raman K. Malhotra, MD, FAAN

Associate Professor, Department of Neurology, Washington University School of Medicine, St. Louis, Missouri

Relationship Disclosure: Dr Malhotra has received personal compensation for serving on the board of directors for the American Academy of Sleep Medicine and as a speaker for a boards review course for the American College of Chest Physicians.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Malhotra reports no disclosure.

Jason C. Ong, PhD

Associate Professor, Northwestern University Feinberg School of Medicine, Chicago, Illinois

Relationship Disclosure: Dr Ong has served on the board of directors for the Society of Behavioral Sleep Medicine; on the medical advisory boards for the Hypersomnia Foundation, the Narcolepsy Network, and Wake Up Narcolepsy, Inc; and on the editorial boards for Behavioral Sleep Medicine, the Journal of Clinical Psychology, and SLEEP and has received personal compensation for serving as a consultant for Headspace, Inc. Dr Ong has received grant/research support from the American Academy of Sleep Medicine, Harmony Biosciences, LLC, the National Institutes of Health (K23AT003678, R21NS081088, R01HL114529, and R3AT009551), and Wake Up Narcolepsy and publishing royalties from the American Psychological Association.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Ong reports no disclosure.

Sofia Romero Peralta, MD

Sleep Research Institute, Madrid; Sleep Unit, Respiratory Department, Hospital Universitario Guadalajara, Guadalajara, Spain

Relationship Disclosure: Dr Romero Peralta reports no disclosure.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Romero Peralta reports no disclosure.

Maria Nichole Perez, MD

Affiliate Faculty, The University of Texas at Austin, Dell Medical School, Austin, Texas

Relationship Disclosure: Dr Perez reports no disclosure.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Perez reports no disclosure.

Rachel V. Rose, JD, MBA

Attorney, Rachel V. Rose Attorney at Law, PLLC; Affiliated Faculty, Baylor College of Medicine, Houston, Texas

Relationship Disclosure: Ms Rose serves on the editorial board of BC Advantage and receives book royalties from the American Bar Association.

Unlabeled Use of Products/Investigational Use Disclosure: Ms Rose reports no disclosure.

Rachel Marie E. Salas, MD, MEd, FAAN

Associate Professor, Director, Interprofessional Education and Interprofessional Collaborative Practice for School of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland

Relationship Disclosure: Dr Salas has received grant/research support from the American Medical Association and the Josiah Macy Jr Foundation and publishing royalties from UpToDate, Inc.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Salas reports no disclosure.

Logan Schneider, MD

Staff Neurologist, Stanford/VA Alzheimer’s Research Center, Palo Alto; Affiliated Clinical Assistant Professor of Sleep Medicine, Stanford Sleep Center, Redwood City, California

Relationship Disclosure: Dr Schneider has served as an editorial board member for Practical Neurology and Sleep and Breathing and has received personal compensation for serving on the speakers’ bureau for Harmony Biosciences, LLC, and Jazz Pharmaceuticals, Inc, and as a sleep health consultant for Alphabet Inc. Dr Schneider has received research/grant support as a VISN 21 research fellow from the US Department of Veteran Affairs Mental Illness Research, Education and Clinical Centers.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Schneider reports no disclosure.

Michael H. Silber, MBChB, FAAN

Professor of Neurology, Mayo Clinic College of Medicine and Science; Consultant Neurologist, Mayo Clinic Center for Sleep Medicine, Rochester, Minnesota

Relationship Disclosure: Dr Silber has served on the scientific and medical advisory board of the Restless Legs Syndrome Foundation and as a book review editor for Sleep Medicine. Dr Silber has received publishing royalties from Oakstone and UpToDate, Inc.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Silber discusses the unlabeled/investigational use of antidepressants, benzodiazepines, pramipexole, and topiramate for the management of non–rapid eye movement parasomnias.

Lynn Marie Trotti, MD, MSc

Associate Professor of Neurology, Emory University School of Medicine, Atlanta, Georgia

Relationship Disclosure: Dr Trotti has served on the editorial boards for Current Sleep Medicine Reports, Journal of Clinical Sleep Medicine, and Sleep and has received compensation/honoraria from the American Academy of Neurology, the American Academy of Sleep Medicine, Associated Professional Sleep Societies, the Kentucky Sleep Society, Medscape, Oakstone, and the Society of Behavioral Sleep Medicine and research/grant support from the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NS083748, NS111280, and NS113912) and the American Academy of Sleep Medicine Foundation.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Trotti discusses the unlabeled/investigational use of modafinil/armodafinil, traditional psychostimulants, sodium oxybate, solriamfetol, pitolisant, lithium, clarithromycin, antiepileptic medications (carbamazepine, valproate, phenobarbital, and phenytoin), and methylprednisolone for the treatment of idiopathic hypersomnia or Kleine-Levin syndrome; antidepressants, methamphetamine, and lisdexamfetamine for the treatment of narcolepsy; and pitolisant for cataplexy.

Phyllis C. Zee, MD, PhD

Benjamin and Virginia Boshes Professor in Neurology, Director, Center for Circadian and Sleep Medicine, Chief, Sleep Medicine Division, Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois

Relationship Disclosure: Dr Zee has received personal compensation for serving on scientific advisory boards for Eisai Co, Ltd, Jazz Pharmaceuticals, Inc, and Koninklijke Philips NV; on the editorial board for Sleep Medicine; for providing live and web-based CME lectures for Accredit Education, LLC, Impact Education, LLC, and WebMD LLC; for providing research and educational programs for Eisai Co, Ltd, Jazz Pharmaceuticals, Inc, Koninklijke Philips NV, Merck & Co, Inc, Pear Therapeutics, Inc, Sanofi-Adventis US LLC, and Takeda Pharmaceutical Company Limited; and research/grant support from Apnimed, Harmony Biosciences, LLC, Jazz Pharmaceuticals, Inc, Koninklijke Philips NV, and the National Institutes of Health (R01 HL140580-03, P01 AG011412-20, UG3HL140144-02, R01 AG059291-01, R01HL141881-02, R01HL134015-04, R21DK118503-02, and R01HD097786). Dr Zee has received publishing royalties from Wolters Kluwer and has held stock in Teva Pharmaceutical Industries Ltd.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Zee discusses the unlabeled/investigational use of melatonin for the treatment of circadian rhythm sleep-wake disorders.

Self-Assessment and CME Test Writers

D. Joanne Lynn, MD, FAAN

Associate Dean for Student Life, Clinical Professor of Neurology, The Ohio State University College of Medicine, Columbus, Ohio

Relationship Disclosure: Dr Lynn has received book royalties from Lippincott Williams & Wilkins and has held stock in Abbott Laboratories, AbbVie Inc, Amgen Inc, Bristol-Myers Squibb Company, CVS Health Corporation, Express Scripts Holding Company, General Electric, Merck & Co, Inc, and Zimmer Biomet.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Lynn reports no disclosure.

James W. M. Owens Jr, MD, PhD

Associate Professor of Neurology, Adjunct Associate Professor of Pediatrics, University of Washington School of Medicine, Seattle, Washington

Relationship Disclosure: Dr Owens has served as CME co-editor for Neurology and has received publishing royalties from UpToDate, Inc.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Owens reports no disclosure.

© 2020 American Academy of Neurology.